Nicotinamide - Hanlim Pharm
Latest Information Update: 03 Jan 2024
At a glance
- Originator Hanlim Pharmaceutical
- Class Amides; Antiacnes; Antibacterials; Eye disorder therapies; Nicotinic acids; Small molecules; Vitamins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Glaucoma
Most Recent Events
- 16 Sep 2022 Clinical trials in Glaucoma in South Korea (PO) (NCT06078605)